14-day Premium Trial Subscription Try For FreeTry Free
$0.0200
+0 (+0%)
At Close: May 03, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $141.16 $183.01 Friday, 3rd May 2024 CALA stock ended at $0.0200. During the day the stock fluctuated 0% from a day low at $0.0200 to a day high of $0.0200.
90 days $141.16 $227.30
52 weeks $84.73 $227.30

Historical Calithera Biosciences prices

Date Open High Low Close Volume
May 04, 2023 $0.0100 $0.0325 $0.0100 $0.0250 11 035
May 03, 2023 $0.0250 $0.0325 $0.0250 $0.0250 17 942
May 02, 2023 $0.0250 $0.0290 $0.0250 $0.0250 5 616
May 01, 2023 $0.0150 $0.0369 $0.0150 $0.0250 28 041
Apr 28, 2023 $0.0100 $0.0450 $0.0100 $0.0200 140 906
Apr 27, 2023 $0.0400 $0.0520 $0.0400 $0.0400 23 730
Apr 26, 2023 $0.0410 $0.0580 $0.0410 $0.0422 12 974
Apr 25, 2023 $0.0400 $0.0580 $0.0400 $0.0400 5 869
Apr 24, 2023 $0.0450 $0.0450 $0.0400 $0.0400 8 450
Apr 21, 2023 $0.0400 $0.0400 $0.0400 $0.0400 1 376
Apr 20, 2023 $0.0410 $0.0550 $0.0410 $0.0410 20 539
Apr 19, 2023 $0.0400 $0.0569 $0.0400 $0.0410 567
Apr 18, 2023 $0.0411 $0.0520 $0.0411 $0.0520 92 339
Apr 17, 2023 $0.0411 $0.0700 $0.0411 $0.0422 2 866
Apr 14, 2023 $0.0600 $0.0600 $0.0410 $0.0560 4 711
Apr 13, 2023 $0.0400 $0.0560 $0.0400 $0.0560 1 748
Apr 12, 2023 $0.0700 $0.0718 $0.0411 $0.0420 5 835
Apr 11, 2023 $0.0400 $0.0770 $0.0400 $0.0460 8 910
Apr 10, 2023 $0.0450 $0.0799 $0.0420 $0.0520 72 322
Apr 06, 2023 $0.0450 $0.0500 $0.0450 $0.0500 514
Apr 05, 2023 $0.0500 $0.0525 $0.0465 $0.0525 746
Apr 04, 2023 $0.0580 $0.0600 $0.0425 $0.0470 7 719
Apr 03, 2023 $0.0450 $0.103 $0.0410 $0.0590 57 859
Mar 31, 2023 $0.0450 $0.0550 $0.0400 $0.0550 66 403
Mar 30, 2023 $0.0550 $0.0550 $0.0401 $0.0401 25 619
Click to get the best stock tips daily for free!

About Calithera Biosciences

Calithera Biosciences Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginas... CALA Profile

Golden Star

Ticker Date Change Price
CVBF May 01 2.75% $16.75
FTSL May 01 0.282% $46.03
EQC Apr 30 0.694% $18.72
HRB Apr 30 0.635% $47.23
BSCQ Apr 30 0.576% $19.09
BSJP Apr 29 0.306% $22.91
LYG Apr 29 1.56% $2.56
ORA Apr 29 4.68% $64.48
DHT Apr 24 3.10% $11.28
LPLA Apr 19 3.12% $262.59
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT